Tuesday, December 11, 2012

Phendimetrazine

SHARE


Phendimetrazine is also in the phenethylamine class of drug and is sold under the brand names Bontril, Plegine, Prelu-2, and X-Trozine. Phendimetrazine was approved by the FDA in1976 and is meant for the first few weeks of a diet and exercise program for the obese.

Phendimetrazine stimulates the central nervous system, just as phentermine does, but it has more of a noticeable stimulating  effect than  does phentermine.  Phendimetrazine is available as time-release capsules and as a result, patients report having more energy throughout the day, even when they are not active. Phendimetrazine does not have the same level of cravings control  as phentermine.  Phendimetrazine  could be prescribed for the first few weeks of a diet to assist with initial weight loss, after which the patient could be prescribed phentermine to assist with continuing appetite control. Both of these drugs could play a role in an overall plan of weight reduction that includes diet and exercise.
Phendimetrazine can increase blood pressure and is therefore not recommended for people with high blood pressure. Other side effects include dizziness, insomnia, headache, dry mouth,  and constipation. Phendimetrazine can also become habit forming if used beyond the recommended first few weeks of a diet. Used alone, phendimetrazine has not been reported to cause the same types of lung or heart valve problems that Fen- phen or Redux did. However, if phendimetrazine is combined with other appetite suppressants, specifically phentermine, or is used in higher than recommended  doses or for too long, lung and heart valve problems may occur.
SHARE

Author: verified_user

Peace be with you every body, I am so glad to build this site which will be great source for every one interested in our web subject.I promise you to get you all in formations and updates in this field ,please never hesitate to be in touch with me for any help for sure I will be happy to support you. Thank you so much from land of Pyramids.

0 comments: